Venus Remedies gets final Rs 11 Cr AMR milestone from Cipla

Business Updates View source PDF Explain this filing

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.3%Reaction day

₹750.00

prior close

₹779.95

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.4%+4.6% vs market

Pharmaceuticals peers, median of 156sector-2.0%+4.2% vs sector

On the reaction day the stock moved 4.6 pts more than Nifty Microcap 250 and 4.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.3

15m

-0.6

30m

-1.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.3-2.4+4.6-2.0+4.2

Next day

+1.1-0.4+1.5-1.4+2.4

+6.1-1.1+7.2-1.4+7.6

+11.3-0.6+12.0-1.0+12.3

+10.0-0.4+10.4-0.8+10.8

+4.6+0.1+4.4-0.6+5.1

+2.1-1.4+3.5-2.1+4.2

15d

-0.7-1.0+0.3-2.1+1.4

-5.7-0.8-5.0-0.8-4.9

-4.9-0.9-4.0-5.2+0.2

+0.4-11.3+11.7-11.8+12.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Venus Remedies received the final Rs 11 crore milestone payment from Cipla, completing all commercial milestones from their 2019 licensing deal. The patented AMR-focused anti-infective, licensed to Cipla for India marketing, has treated over 1 million patients with no serious adverse events reported. The company highlighted pipeline candidates VRP-034 and MET-X, both granted US FDA QIDP designation.

Likely market impact

Positive — validates 2019 licensing deal completion, reinforces AMR research credibility, and adds modest cash inflow.